Warning letter
Bristol Myers Squibb Holdings Pharma., Ltd. [ARCHIVED]: warning letter of Aug 30, 2010
FDA warning letter UCM225277 · San Juan District Office
Key facts
| Reference number | UCM225277 |
|---|---|
| Company | Bristol Myers Squibb Holdings Pharma., Ltd. [ARCHIVED] |
| Subject | CGMP/QSR/Manufacture/Packing/Storage/Installation/Adulterated |
| Issue date | Aug 30, 2010 |
| Posted date | Aug 30, 2010 |
| Issuing office | San Juan District Office |
| Product type | Drugs |
| CFR sections cited | 211.113(b), 211.192, 211.160(b) |
| Country | 3 |
| Letter on fda.gov | web.archive.org |
At a glance
- 1–9 CFR sections cited
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: